Rituximab as an adjunctive treatment for schizophrenia

4 Likes

Disability was diminished by 64% in patients with schizophrenia week 12.

64% is a lot considering it works for treatment resistant schizophrenia.

1 Like

I worked with monoclonal antibodies in nuclear medicine. The more you use them the more likelihood you get a hama response which is like a allergic response. In which case you have to discontinue. I’ve never read of anyone using monoclonal antibodies typically from mice long term.

2 Likes

Very interesting ! Thanks for the post ! I found there is a clinical trial of this drug ending the 1st January 2026 !

1 Like

This topic was automatically closed 14 days after the last reply. New replies are no longer allowed.